CVE:BTIbiOasis Technologies Stock Price, Forecast & News

C$0.16

0.00 (0.00 %)

(As of 06/5/2020 10:12 AM ET)

Add

Compare

Today's Range

C$0.16

Now: C$0.16▼

C$0.16

50-Day Range

C$0.15

MA: C$0.17▼

C$0.20

52-Week Range

C$0.15

Now: C$0.16▼

C$0.35

Volume35,000 shs

Average Volume38,080 shs

Market CapitalizationC$10.16 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics and imaging agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical needs, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain metastases, glioblastomas, and neurodegenerative diseases. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the BBB; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program, as well with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for biOasis Technologies.

2.7 Community Rank

Outperform Votes
biOasis Technologies has received 54 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
biOasis Technologies has received 45 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
biOasis Technologies has received 54.55% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote “Outperform” if you believe BTI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BTI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
biOasis Technologies does not currently pay a dividend.
Dividend Growth
biOasis Technologies does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, biOasis Technologies insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of biOasis Technologies is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of biOasis Technologies is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

0.54 out of 5 stars

Industry, Sector and Symbol

Stock Exchange CVE

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolCVE:BTI

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.bioasis.ca

Phone+1-604-2957014

Debt

Debt-to-Equity RatioN/A

Current Ratio0.41

Quick Ratio0.33

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesC$718,475.00

Price / Sales14.14

Cash FlowC$0.01 per share

Price / Cash Flow20.00

Book ValueC($0.03) per share

Price / Book-5.93

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares63,508,000

Market CapC$10.16 million

Next Earnings Date7/24/2020 (Estimated)

OptionableOptionable

Receive BTI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTI and its competitors with MarketBeat's FREE daily newsletter.

biOasis Technologies (CVE:BTI) Frequently Asked Questions

How has biOasis Technologies' stock been impacted by COVID-19 (Coronavirus)?

biOasis Technologies' stock was trading at C$0.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BTI shares have decreased by 15.8% and is now trading at C$0.16. View which stocks have been most impacted by Coronavirus.

When is biOasis Technologies' next earnings date?

biOasis Technologies is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for biOasis Technologies.

Has biOasis Technologies been receiving favorable news coverage?

Media coverage about BTI stock has trended somewhat negative this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. biOasis Technologies earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutbiOasis Technologies.

Who are some of biOasis Technologies' key competitors?

Some companies that are related to biOasis Technologies include Covalon Technologies (COV), Race Oncology (RAC), AmpliPhi Biosciences (ARMP), Microbix Biosystems (MBX), Oragenics (OGEN), Proteomics Int Lab (PIQ), IntelGenx Technologies (IGX), Ixico (IXI), Pharmaust (PAA), Actinium Pharmaceuticals (ATNM), Kazia Therapeutics (KZA), NovaBay Pharmaceuticals (NBY), Biocardia (BCDA), Nuformix (NFX) and ImmuPharma (IMM). View all competitors.

What other stocks do shareholders of biOasis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other biOasis Technologies investors own include Praxair (PX), OrganiGram (OGI), Morningstar (MORN), Five Below (FIVE), Extendicare (EXE), General Cannabis (CANN), Blackstone Mortgage Trust (BXMT) and Bank of America (BAC).

Who are biOasis Technologies' key executives?

biOasis Technologies' management team includes the following people:

Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chair, CEO & Pres (Age 61)
Ms. Christine Antalik, Chief Financial Officer (Age 48)
Mr. Graeme Dick, Director of Investor Relations
Mr. Kim Elton, Director of Marketing
Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer

What is biOasis Technologies' stock symbol?

biOasis Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BTI."

How do I buy shares of biOasis Technologies?

Shares of BTI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is biOasis Technologies' stock price today?

One share of BTI stock can currently be purchased for approximately C$0.16.

How big of a company is biOasis Technologies?

biOasis Technologies has a market capitalization of C$10.16 million and generates C$718,475.00 in revenue each year.

What is biOasis Technologies' official website?

The official website for biOasis Technologies is www.bioasis.ca.

How can I contact biOasis Technologies?

biOasis Technologies' mailing address is 130-10691 Shellbridge Way, RICHMOND, BC V6X 2W8, Canada. The company can be reached via phone at +1-604-2957014.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

CVE:BTIbiOasis Technologies Stock Price, Forecast & News

Adding